Business Context and Reporting Period
Company: Prothena Corporation plc (Ireland)
Filing Type: Form 8-K (Current Report)
Date of Report: December 9, 2015
Subject: Approval of amendments to the Prothena Biosciences Inc. Amended and Restated Severance Plan by the Compensation Committee.
Key Financial Metrics
This filing does not contain financial performance data. The document focuses exclusively on corporate governance and executive compensation arrangements. No revenue, profit, cash flow, margin, debt, or liquidity figures are provided in this text.
Material Changes
The Compensation Committee approved two specific amendments to the Severance Plan for named executive officers (excluding Dale B. Schenk, who is covered under a separate agreement):
- Termination Date: The plan no longer automatically terminates on December 31, 2015. Instead, the termination date is now determined by the board of directors of Prothena Biosciences Inc.
- Health Coverage Extension: Continuation health coverage for qualifying terminations occurring within two years after a change in control has increased from 12 months to 18 months.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the amended terms remain materially consistent with previously disclosed terms, aside from the specific changes noted above.
Risks and Contingencies: No new risks or contingencies are disclosed in this report. The filing references the full Severance Plan attached as Exhibit 10.1 for complete terms.
Investor Verification Checklist
- Review Exhibit 10.1 (Prothena Biosciences Inc Amended and Restated Severance Plan) for the complete legal text of the amendments.
- Verify the specific eligibility criteria for the extended 18-month health coverage post-change in control.
- Confirm the current status of the plan's termination date as determined by the board of directors.
- Note that Dale B. Schenk is excluded from this specific plan and operates under a separate employment agreement.